Get the Stockscreener App
52.12
2.89%
-1.55
After Hours:
52.29
0.17
+0.33%
Structure Therapeutics Inc Adr stock is traded at $52.12, with a volume of 1.64M.
It is down -2.89% in the last 24 hours and up +35.20% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$53.67
Open:
$53.93
24h Volume:
1.64M
Relative Volume:
1.86
Market Cap:
$3.70B
Revenue:
-
Net Income/Loss:
$-170.73M
P/E Ratio:
-19.36
EPS:
-2.6921
Net Cash Flow:
$-159.70M
1W Performance:
+8.22%
1M Performance:
+35.20%
6M Performance:
-25.06%
1Y Performance:
+154.12%
1-Day Range:
$51.25
$54.66
1-Week Range:
$48.17
$55.00
52-Week Range:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
52.12 | 3.81B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - TradingView
Form 4 Structure Therapeutics Inc ADR For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
(GPCR) Risk Channels and Responsive Allocation - Stock Traders Daily
Structure Therapeutics, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:GPCR) - TradingView
Form 144 Structure Therapeutics Inc. For: 25 June By Investing.com - Investing.com South Africa
[144] Structure Therapeutics Inc. SEC Filing - Stock Titan
Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Analysts Conflicted on These Healthcare Names: Phreesia (PHR) and Novo Nordisk (NVO) - The Globe and Mail
Shareholders Approve Directors, Auditors at 2026 Meeting - The Globe and Mail
Director at Structure Therapeutics (NASDAQ: GPCR) gets 39,453 options - Stock Titan
Structure Therapeutics (GPCR) director receives 39,453 share options at $15 - Stock Titan
Structure Therapeutics (GPCR) grants 39,453-share option award to director - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) reports 2026 shareholder voting outcomes - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged - TipRanks
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - The Manila Times
Why Structure Therapeutics Stock Is Sliding Today - TipRanks
Zevra Therapeutics (NASDAQ: ZVRA) vote keeps classified board structure - Stock Titan
Oral obesity drug helped people lose up to 16% body weight in trial - Stock Titan
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues? - TradingView
Why Structure Therapeutics Stock Is Surging Higher - TipRanks
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst? - TradingView
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks - Stock Titan
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth? - TradingView
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - AOL.com
Why (GPCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why Structure Therapeutics Shares Are Sinking Today - TipRanks
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape - Intellectia AI
Monashee Scales Back Its Bet on Structure Therapeutics - Yahoo Finance
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Globe and Mail
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Motley Fool
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):